Kura Oncology (KURA) Non-Current Assets (2014 - 2026)
Kura Oncology (KURA) reported Non-Current Assets of $28.8 million for Q1 2026, up 47.04% year-over-year from $19.6 million in Q1 2025, and down 3.13% on a QoQ basis from $29.7 million in Q4 2025.
Kura Oncology (KURA) has 13 years of Non-Current Assets data on file, last reported at $28.8 million in Q1 2026.
- Quarterly Non-Current Assets rose 47.04% year-over-year to $28.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $109.5 million (up 66.24% YoY) and the FY2025 annual result came in at $29.7 million, up 93.74% from the prior year.
- Non-Current Assets declined to $28.8 million in Q1 2026 per KURA's latest filing, from $29.7 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $29.7 million in Q4 2025 and bottomed at $9.1 million in Q2 2023.
- The 5-year median for Non-Current Assets is $15.3 million (2024), against an average of $16.8 million.
- The widest annual swing landed in 2023, when Non-Current Assets slipped 21.89%; it then jumped 93.74% in 2025.
- Tracing KURA's Non-Current Assets over 5 years: stood at $9.9 million in 2022, then jumped by 66.54% to $16.5 million in 2023, then fell by 6.83% to $15.3 million in 2024, then jumped by 93.74% to $29.7 million in 2025, then decreased by 3.13% to $28.8 million in 2026.
- Per Business Quant, the three latest KURA Non-Current Assets figures stand at $28.8 million (Q1 2026), $29.7 million (Q4 2025), and $28.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Kura Oncology | 801.92 Mn | 801.92 Mn | 18.00 Mn | 28.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.77 Mn |
| Dec 31, 2025 | 29.70 Mn |
| Sep 30, 2025 | 28.72 Mn |
| Jun 30, 2025 | 22.35 Mn |
| Mar 31, 2025 | 19.57 Mn |
| Dec 31, 2024 | 15.33 Mn |
| Sep 30, 2024 | 15.65 Mn |
| Jun 30, 2024 | 15.35 Mn |
| Mar 31, 2024 | 16.07 Mn |
| Dec 31, 2023 | 16.45 Mn |
| Sep 30, 2023 | 13.85 Mn |
| Jun 30, 2023 | 9.09 Mn |
| Mar 31, 2023 | 9.53 Mn |
| Dec 31, 2022 | 9.88 Mn |
| Sep 30, 2022 | 11.60 Mn |
| Jun 30, 2022 | 11.64 Mn |
| Mar 31, 2022 | 11.55 Mn |
| Dec 31, 2021 | 11.76 Mn |
| Sep 30, 2021 | 12.24 Mn |
| Jun 30, 2021 | 11.26 Mn |
| Mar 31, 2021 | 9.56 Mn |
| Dec 31, 2020 | 9.92 Mn |
| Sep 30, 2020 | 10.66 Mn |
| Jun 30, 2020 | 10.81 Mn |
| Mar 31, 2020 | 5.33 Mn |
| Dec 31, 2019 | 2.37 Mn |
| Sep 30, 2019 | 1.65 Mn |
| Jun 30, 2019 | 1.78 Mn |
| Mar 31, 2019 | 2.03 Mn |
| Dec 31, 2018 | 1.18 Mn |
| Sep 30, 2018 | 1.11 Mn |
| Jun 30, 2018 | 1.09 Mn |
| Mar 31, 2018 | 1.10 Mn |
| Dec 31, 2017 | 1.21 Mn |
| Sep 30, 2017 | 1.19 Mn |
| Jun 30, 2017 | 1.11 Mn |
| Mar 31, 2017 | 1.29 Mn |
| Dec 31, 2016 | 1.01 Mn |
| Sep 30, 2016 | 589,000.00 |
| Jun 30, 2016 | 323,000.00 |
| Mar 31, 2016 | 307,000.00 |
| Dec 31, 2015 | 390,000.00 |
| Sep 30, 2015 | 521,000.00 |
| Jun 30, 2015 | 343,000.00 |
| Mar 31, 2015 | 189,000.00 |
| Dec 31, 2014 | 182,000.00 |